HepatologyNews.net

Hepatology Xagena

Xagena Mappa
Medical Meeting
Dermabase.it
Reumabase.it

Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus ( HCV ) infection.In the phase 2b, randomized, open-label trial of Faldaprevir ( a proteas ...


There is a need for Interferon-free treatment regimens for hepatitis C virus ( HCV ) infection. The goal of a study was to evaluate ABT-450, a potent HCV NS3 protease inhibitor, combined with low-dose ...


The standard treatment for hepatitis C virus ( HCV ) infection is Interferon, which is administered subcutaneously and can have troublesome side effects.Researchers have evaluated Sofosbuvir ( Sovaldi ...


A study has evaluated the efficacy and safety of a new treatment regimen consisting of dose-dense Cisplatin-based chemotherapy and radical surgery in children with high-risk hepatoblastoma.SIOPEL-4 wa ...


Hepatic encephalopathy ( HE ) is associated with poor prognosis in cirrhosis. Drugs used in the treatment of hepatic encephalopathy are primarily directed at the reduction of the blood ammonia levels. ...


Data have shown that second-generation protease inhibitor Faldaprevir, when used in combination with Pegylated Interferon and Ribavirin, was effective even with the presence of naturally-occurring mut ...


New data from Interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of Faldaprevir and Deleobuvir plus Ribavi ...


Interim data from Phase 2a hepatitis C ( HCV ) clinical trial that showed all patients ( 13/13 ) who reached the 4-week post-treatment follow-up had undetectable levels of hepatitis C virus ( SVR4 ) w ...


In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of 3D regimen achieved a sustained virologic response at 12 weeks post-treatment ( SVR12 ) of 96%. The majority of patie ...


Interim data from the ongoing C-WORTHY study, a phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus ( H ...


The results from the pivotal Phase 3 STARTVerso trial of Faldaprevir in combination with Pegylated Interferon and Ribavirin ( PegIFN/RBV ) were presented. In previously untreated patients with genotyp ...


The results from four Phase 3 clinical trials ( NEUTRINO, FISSION, POSITRON and FUSION ) evaluating Sofosbuvir ( Sovaldi ), an investigational once-daily nucleotide NS5B inhibitor for the treatment of ...


A study has revealed that virological breakthrough is common in patients receiving nucleoside analogs ( NUCs ) for chronic hepatitis B. Nearly 40% of the virological breakthrough found were not relate ...


The researchers tested whether adjunct Erlotinib ( Tarceva ), a direct and reversible EGFR tyrosine kinase inhibitor, could have synergistic or additive antitumor effects when used with Sorafenib ( Ne ...


Researchers at Cedars-Sinai Medical Center and 50 other Centers found that weight-based dosing of Taribavirin ( Viramidine ) reduces rates of anemia while increasing sustained virologic response ( SVR ...